# MRT-2359

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/mrt-2359
Canonical HTML page: https://getbiobrief.com/entity/mrt-2359

## Timeline

- **2026-03-17**: Q4 2025 Earnings — Reported year-end financial results and updated 2027 cash runway.
- **2026**: Anticipated Milestone — Expected Phase 1 data readout for MRT-6160 in autoimmune diseases.
- **2025-06-15**: MRT-2359 Update — Released preliminary Phase 1 safety and target engagement data.
- **2024-10-28**: Novartis Partnership — Signed global licensing deal for MRT-6160 worth up to $2.1B.

## Recent coverage (1 stories)

### Monte Rosa Therapeutics Leverages Novartis Deal to Extend Runway into 2027
2026-03-19 14:20:05 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Monte Rosa Therapeutics reported quarterly results highlighting a robust cash position following its $2.1 billion Novartis partnership. The company is accelerating its molecular glue degrader pipeline with a strategic pivot toward high-value immunology indications.
Full story: https://getbiobrief.com/story/monte-rosa-therapeutics-earnings-analysis-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.